Month: February 2024

TORONTO and MANCHESTER, England, Feb. 05, 2024 (GLOBE NEWSWIRE) — Onex Corporation (“Onex”) (TSX: ONEX) today announced that Onex Partners V has completed a majority investment in Morson Group (“Morson” or the “Company”), a leading UK engineering and technical staffing and workforce solutions business, with growing operations in the UK, U.S., Italy, Canada and Australia. The investment has been made alongside the founding family CEO Ged Mason and members of the management team. Financial terms were not disclosed. Headquartered in Manchester, United Kingdom, Morson Group provides services including: (i) contingent workforce solutions, relating to the placement of engineering, IT and technical contractors with customers, (ii) permanent recruitment and recruitment process outsourcing (RPO), (iii) related planning workforce support...

— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company to host webcasted conference call today at 8:30am EST — MELVILLE, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced the public availability of a poster, presented yesterday at the Orthopaedic Research Society (ORS) 2024 Annual Meeting, which describes preliminary 26 and 52 week blinded data from the ongoing Phase 2 clinical trial of the Company’s lead clinical candidate, BRTX-100, in subjects with chronic lumbar disc disease (“cLDD”). The presented poster, titled “Autologous Stem Cell Therapy for Chronic Lumbar Disc Disease; Initial Phase 2 Clinical Safety and Feasibility...

CARLSBAD, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the issuance of its second United States Patent No: 11,850,162 entitled “Body Density Scan Result-Matched Orthopedic Implants and Methods of Use” for The World’s First DEXA Technology™ Patient-Matched Implant Technology. Aurora Spine’s first-of-its kind DEXA Technology™ is designed to match a patient’s bone density, promote bone in-growth while maintaining the biomechanical structure and bone support. This patent will be utilized to create implants that match the patient’s specific bone density based on a DEXA Scan/T-score allowing for the best bone fusion treatment and most favorable...

ROGERS, Ark., Feb. 05, 2024 (GLOBE NEWSWIRE) — America’s Car-Mart, Inc. (NASDAQ: CRMT) today announced it will release fiscal 2024 third quarter financial results on Friday, March 8, 2024, before the market opens and senior management will host a conference call at 11:00 a.m ET to discuss the results. Participants may access the conference call via webcast using this link: Webcast Link Here. To participate via telephone, please register in advance using this Registration Link. Upon registration, all telephone participants will receive a one-time confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call. All participants are encouraged to dial-in 10 minutes prior to the start time. A replay of the conference call and webcast will be available...

88 patients enrolledJanuary being the highest enrollment month since the launch of TigrisTORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Enrollment:Robust enrollment activity continues throughout 2024:88 patients enrolled to-dateSix patients enrolled in the month of January, which is the highest monthly enrollment experienced since the start of the Tigris study One patient enrolled in February to dateClosing in on the interim enrollment target of...

Lawsuit alleges false and misleading advertising and promotion of unapproved cantharidin-containing drugs by Dormer Laboratories in violation of federal and state law WEST CHESTER, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or, the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has filed a lawsuit in the Eastern District of Pennsylvania against Dormer Laboratories Inc., a Canada corporation (“Dormer Labs”) requesting, among other relief, that the court enjoin Dormer Labs from marketing, selling, and distributing drugs containing cantharidin in the United States, as well as compensatory, statutory and punitive damages for Dormer Labs’ violations of the federal Lanham Act and Pennsylvania...

MIAMI, Feb. 05, 2024 (GLOBE NEWSWIRE) — Global Crossing Airlines Group, Inc. (JET: Cboe CA; JET.B: Cboe CA; JETMF: OTCQB) (“GlobalX”) announces the appointment, effective today, of Chris Jamroz as Executive Chairman and Ryan Goepel as President. Mr. Goepel will continue to serve as Chief Financial Officer. The Board of Directors (the “Board”) and Edward J. Wegel, the Company’s Chief Executive Officer, have agreed that Mr.Wegel will resign his duties, rights, and obligations as an officer and Chairman and CEO of the Company, effective immediately. While the Company continues its search for a successor, the leadership team will report to the Executive Chairman of the Board. Ed Wegel will continue to serve on GlobalX’s Board of Directors and as a GlobalX Senior Advisor. “It has been a great privilege for me to have helped build GlobalX...